Institut De Recherches Internationales Servier

This study is testing whether adding a new drug called AG-120 (ivosidenib) to standard chemotherapy (azacitidine) works better than the standard chemo alone for adults with a specific type of newly diagnosed acute myeloid leukemia (AML). It is for patients aged 18 and older who a…

This early-stage study is testing the safety and initial effects of combining two drugs, vorasidenib and pembrolizumab, in adults with a recurrent or worsening type of brain tumor called glioma. The goal is to see if this combination can help control the cancer by boosting the im…

This early-stage trial aimed to test the safety and initial effectiveness of a new drug called S095033 when combined with standard chemotherapy (paclitaxel) for people with advanced esophageal cancer that had stopped responding to previous treatments. The study was designed to fi…

This study is testing a new combination of two drugs, vorasidenib and temozolomide, for people with a specific genetic type of brain tumor called an IDH-mutant glioma. The first part of the study aims to find the safest and most effective dose. The second part will see how well t…

This study compares two different drug combinations for people with metastatic colorectal cancer who cannot receive intensive chemotherapy. Researchers want to see if one combination works better than the other at controlling cancer growth and extending life. The trial involves 8…

This early-stage trial is testing a new cancer drug called S095029, both alone and combined with an existing immunotherapy drug (Sym021). The study aims to find safe doses and see if these treatments show early signs of fighting advanced solid tumors in patients who have run out …